Boris Hadaschik

Urologic oncologist & surgeon; Chairman, Department of Urology, Pediatric Urology and Urooncology, University Hospital Essen

[Boris Hadaschik @ProfHadaschik]

@Prof_Nick_James agree that comparison to ENZARAD and ATLAS very useful - however challenging because of slightly different entry criteria and endpoints. PROTEUS had specific demands for high numbers of involved cores. cT staging not easy to compare because of differences in use of DRE vs imaging

[Boris Hadaschik @ProfHadaschik]

@DrSpratticus @ChapinMD In the NED at 4yrs data there is a lot of censoring we need to understand better. The BCR rates look better.
MFS on conventional imaging is not negative but premature, given the low number of events.

[Boris Hadaschik @ProfHadaschik]

To cure a larger fraction of patients with high risk disease we will need a truly integrated approach. I am surpised that there was not more salvage RT in PROTEUS.

[Boris Hadaschik @ProfHadaschik]

Perioperative Apalutamide in High-Risk Localized Prostate Cancer | New England Journal of Medicine https://t.co/rYijKEbAMH

Honored to be involved - lots to discuss and lots to come

[Boris Hadaschik @ProfHadaschik]

It adds data to the discussion. The RP only substudy comes next year.
SPCG15 will be very important.

Primary PET staging not available in PROTEUS.

Comparison to ENZARAD and ATLAS will be interesting…

I am very happy that PROTEUS is positive.

[Boris Hadaschik @ProfHadaschik]

@DrSpratticus @TylerSbrt The assumptions were complicated because of the dual primary endpoint (at least for a Urologist…) Will be shown on Sunday. Furthermore PSMA onboarded during the trial. Many important clinical endpoints and many discussions to come.

[Boris Hadaschik @ProfHadaschik]

@yekeduz_emre @montypal @ASCO @OncoAlert @DrChoueiri @NazliDizman @nataliagandur @neerajaiims @DrYukselUrun @BourlonMaite @DrRanaMcKay @DanaFarber_GU and PROTEUS - plenary on Sunday

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study

https://t.co/oA3mci76XD

In an international registry study of 11,154 patients, investigators developed PPP3 nomograms integrating clinical features and PSMA-PET PROMISE metrics to predict 3-, 5-, and 7-year overall survival in #ProstateCancer

Developed and validated across 35 global sites,
✅ Models demonstrated strong discrimination (C-index ~0.83–0.84).
✅PPP3 performed as well as or better than existing clinical risk scores, supporting PSMA-PET–based risk stratification for guidelines, clinical decision-making, and trial design.

@CalaisJeremie
@DrMHofman
@thomashopemd
@drlouiseemmett
@DrAGafita
@ProfKHerrmann
@ProfHadaschik
@Dr_K_Rahbar
@bjartell

@OncoAlert 🚨
@silkegillessen
@AOmlin
@weoncologists
#EAU26

[Boris Hadaschik @ProfHadaschik]

back on X for scientific reasons because the alternative platforms unfortunately did not fulfill my expectations

[Boris Hadaschik @ProfHadaschik]

I am leaving X with a sad eye moving on to more reasonable platforms.

[Pierre Blanchard, MD @PBlanchardMD]

PEACE-1 RT is now published online at @TheLancet

Some differences with STAMPEDE

Key messages: RT to prostate in M1 #prostatecancer
1. improves rPFS but not OS in low volume
2. improves CRPC-FS & reduces serious GU SAE irrespective of volume

Full text: https://t.co/bfPzTdWTro

[Boris Hadaschik @ProfHadaschik]

@niklas_kluemper @ViktorGruenwald @ProfKHerrmann @urotoday @OncoAlert Having multiple options always better. Clinical trials are underway. If we only knew beforehand which tracer worked best in which indication. Histopathology of the primary can help.

[Boris Hadaschik @ProfHadaschik]

Happy to share: Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer - ScienceDirect https://t.co/rbpdSScJHY

[silke gillessen @Silke_Gillessen]

We are very proud that the paper is online! Sincere thanks to our scientific committee and all panellists. Manuscript is open access, please use and distribute it! Hope to see you at the first edition of @APCCC_Lugano Diagnostics @ProfKHerrmann @stefanofanti4

[Alastair Lamb @LambAlastair]

Delighted to share our latest on #18F_PSMA_PET just published in cool new @JUOpenPlus!

•n=1335 scans from 1220 men
•1°: PSMA 96% vs MRI 89% sens. for pros lesions at RP
•2°: PSA 0.2-0.49 post RP/RT ➡️ avidity in 57.8%

BUT high false +ves (esp ribs)

https://t.co/xlZzcsApIo

[Dr. Jason Efstathiou @drjefstathiou]

Sharing key takeaways from my #ASTRO2024 presentation! I'm grateful for the support I've received—thank you, @ASTRO, @MGHCancerCenter @theNCI & @Pcfnews. It’s a win for our field that both #ProtonTherapy & #IMRT are equally highly effective for localized #ProstateCancer.

[Dr. Bishoy M. Faltas @FaltasLab]

🚀Big News! Excited to share our work “The Interplay of Mutagenesis and ecDNA Shapes Urothelial Cancer Evolution” published in @Nature! https://t.co/sU6uF9rNvI

[Vincent J Gnanapragasam @VincentGnanapr3]

Our latest paper on risk stratified prostate cancer testing - TARGET study, a simultaneous evaluation of PRS, PSAd, F/T PSA, phi in a PSA triggered MRI diagnostic pathway + testing different defn of ‘clinical significance’ https://t.co/6yZGFFZ5RQ

[NEJM @NEJM]

In patients with muscle-invasive bladder cancer, extended lymphadenectomy did not improve disease-free or overall survival as compared with the standard procedure and was associated with higher morbidity and mortality. Full SWOG S1011 trial results: https://t.co/mYGY3Zd2MX